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Abstract 
Objective 
Atrial fibrillation (AF) is the most common cardiac arrhythmia and an important risk factor 
for stroke. Treatment with anticoagulants substantially reduces risk of stroke. Current 
prevalence and treatment rates of AF in the UK, and changes in recent years, are not known. 
The aim of this analysis was to determine trends in age-sex specific prevalence and treatment 
of AF in the UK from 2000 to 2016. 
Methods 
Seventeen sequential cross-sectional analyses were carried out between 2000 and 2016 using 
a large database of electronic primary care records of patients registered with UK general 
practitioners. Stroke risk was assessed using CHA2DS2-VASc score. 
Results 
Age-sex standardised AF prevalence increased from 2.14% (95% CI 2.11 to 2.17) in 2000 to 
3.29% (95% CI 3.27 to 3.32) in 2016. Between 2000 and 2016, the proportion of patients 
with AF prescribed anticoagulants increased from 35.4% (95% CI 34.7 to 36.1) to 75.5% 
(95% CI 75.1 to 75.8) in those with high stroke risk (p for change over time < 0.001) and 
from 32.8% (95% CI 30.5 to 35.2) to 47.1% (95% CI 45.4 to 48.7) in those with moderate 
stroke risk (p < 0.001). In patients with low risk of stroke, the proportion decreased from 
19.9% (95% CI 17.8 to 22.2) to 9.7% (95% CI 8.4 to 11.1) (p < 0.001). 
Anticoagulant prescribing performance varied between practices; in 2016 the proportion of 
eligible patients treated was 82.9% (95% CI 82.2 to 83.7) and 62.0% (95% CI 61.0 to 63.0) in 
the highest- and lowest-performing practice quintiles respectively. There was poor agreement 
in individual practice performance over time from 2006 to 2016: linear-weighted κ = 0.10 
(95% CI 0.02 to 0.19). 
Conclusions 
From 2000 to 2016, the prevalence of recorded AF has increased in all age groups and both 
sexes. Anticoagulant treatment of eligible patients with AF has more than doubled, with 
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marked improvements since 2011, alongside a reduction in the use of anticoagulants in 
ineligible patients with AF. 
Key Questions 
What is already known about this subject? 
Atrial fibrillation (AF) is associated with a substantial increase in risk of stroke, but 
anticoagulant prophylaxis reduces this risk by about two thirds. Current prevalence and 
treatment rates of AF in the UK, and changes in recent years, are not known. 
What does this study add? 
Between 2000 and 2016, age-sex standardised AF prevalence increased from 2.02% to 
3.29%. Over the same period, the proportion of patients with AF prescribed anticoagulants 
increased from 35.4% to 75.5% in those with high stroke risk and from 32.8% to 47.1% in 
those with moderate stroke risk. In patients with low stroke risk, the proportion decreased 
from 19.9% to 9.7%. 
How might this impact on clinical practice? 
There remains scope for improvement in the treatment of patients with AF, in particular those 
with moderate risk of stroke. 
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Introduction 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated 
with a five-fold increase in risk of stroke.1 Stroke risk is reduced by approximately two thirds 
by warfarin or novel oral anticoagulants (NOACs); aspirin is considerably less effective but 
has a similar risk of major bleeding.2,3,4 AF accounts for 14% of all strokes, and strokes 
associated with AF are associated with higher mortality.5 
Anticoagulant prophylaxis has been recommended for patients with AF at elevated risk of 
stroke since 2006.6,7,8  Current UK and European guidelines recommend anticoagulants for all 
patients with AF with a CHA2DS2-VASc score ≥2, and recommend considering them for men 
with a CHA2DS2-VASc score of 1.7,9 Earlier guidelines recommended anticoagulants for 
patients with a CHADS2 score ≥2, anticoagulants or aspirin for those with a CHADS2 score 
of 1, and aspirin for those with a CHADS2 score of 0.1,10 This includes all AF types 
(paroxysmal, persistent or permanent) and atrial flutter, since all groups are at increased risk 
of stroke.11,12 
There is substantial evidence demonstrating both undertreatment of moderate to high risk 
patients and overtreatment of low risk patients in the UK over the past decade.13,14 Both may 
be associated with increased risk of stroke.15 Low AF treatment rates have also been found 
internationally;16,17 however, studies in Germany and Switzerland have reported 
anticoagulant use in ≥80% of eligible patients, in both primary and secondary care settings, 
suggesting that higher rates of anticoagulant use are possible.18,19 
Current prevalence of diagnosed AF and recent AF treatment patterns are unknown. The 
purpose of this study was to provide a broader understanding of the prevalence and treatment 
of AF in the UK over the past 17 years. The primary objectives were to determine age-sex 
specific prevalence of diagnosed AF in the UK each year from 2000 to 2016; to determine the 
proportions of patients with AF prescribed anticoagulant treatment, antiplatelets only, or no 
treatment, stratifying patients according to stroke risk; to investigate trends in prevalence and 
treatment over the 17 years; and to investigate variations in AF diagnosis and anticoagulant 
prescribing between general practices. 
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Methods 
See Supplementary Appendix for further detail. 20 
Data Source 
Analysis was performed using patient data from The Health Improvement Network (THIN), 
an anonymised database of electronic primary care records from UK general practices which 
use Vision software. THIN includes coded data on patient characteristics, prescriptions, 
consultations, diagnoses and primary care investigations. 
Practices were eligible for inclusion in the study from the latest of the practice acceptable 
mortality recording (AMR) date,21 Vision installation date, and study start date (one year 
prior to the first census date). All analyses were conducted using Stata IC version 14.2. 
Study Design 
Seventeen sequential cross-sectional analyses were performed on 1st December each year 
from 2000 to 2016 (census dates). To determine prevalence of AF, all patients aged 35 years 
and over and registered at least one year prior to the census date were eligible for inclusion in 
the denominator; exposure was a record of AF prior to the census date with no clinical code 
indicating ‘AF resolved’ recorded after the last recorded AF code and prior to the census 
date. To investigate treatment rates, patients aged 35 years and over, with a recorded 
diagnosis of AF and registered at least one year prior to the census date were eligible for 
inclusion; patients with a clinical code indicating ‘AF resolved’ recorded after the last 
recorded AF code and prior to the census date were excluded. 
Analysis 
Crude age-sex specific prevalence of diagnosed AF was calculated on each of the seventeen 
census dates. 95% confidence intervals (95%CI) for proportions were calculated using the 
exact binomial method. Chi-squared tests were used to calculate p-values for trends over 
time. Prevalence in each year was directly age-sex standardised using the 2016 age-sex 
distribution as the standard. 
Proportions of patients prescribed anticoagulants, antiplatelets only, and neither were 
calculated with 95%CIs for proportions on each of the seventeen census dates. Patients were 
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stratified according to stroke risk. In primary analysis, stroke risk and eligibility for treatment 
were defined in accordance with current guidelines using CHA2DS2-VASc score; male 
patients with a CHA2DS2-VASc score ≥1 and female patients with a CHA2DS2-VASc score 
≥2 were eligible for anticoagulant treatment.7,9 In sensitivity analysis, stroke risk/eligibility 
was defined using CHADS2 score (those with a score ≥1 were eligible for treatment), as the 
CHADS2 score has been in use for a greater proportion of the study period than CHA2DS2-
VASc score.1,7,22 In a further sensitivity analysis, eligibility for treatment was determined by 
CHA2DS2-VASc score, but patients with contraindications to anticoagulants were considered 
ineligible. Trends over time were plotted and chi-squared tests used to determine if any 
observed trends were statistically significant. 
Practice-level variation 
Variation in diagnosis of AF between practices was assessed by determining the interquartile 
range (IQR) for age-sex standardised practice-level prevalence of AF (directly standardised 
to the 2016 THIN age-sex distribution). 
To investigate inter-practice variation in anticoagulant prescribing to eligible patients over 
time, the performance of practices in the highest and lowest quintiles of anticoagulant 
prescribing were plotted for each year from 2000 to 2016; all practices contributing to the 
dataset were included. 
Prescribing performance of individual general practices was assessed over the period 2006 to 
2016; only practices contributing data on each of the 11 census dates were included. Linear-
weighted kappa coefficients for ordered categories were calculated to ascertain whether 
practice performance remained constant over the period. 
Results 
Prevalence of atrial fibrillation 
A total of 37,987,313 patient records belonging to 5,058,699 unique patients from 744 
general practices were included in the analysis across the 17 census dates from 2000 to 2016: 
a median of 2,394,593 (IQR 1,881,881-2,698,834) patients per year (patient characteristics 
are shown in Supplementary Table 1). 
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Crude prevalence of recorded AF in adults aged 35 years and over increased 63%, from 
2.02% (95%CI 1.99-2.04) in 2000 to 3.29% (3.27-3.32) in 2016 (Figure 1, Supplementary 
Table 2). Directly standardised prevalence increased by 50% from 2.14% (2.11-2.17) in 
2000. 
Between 2000 and 2016, prevalence of diagnosed AF increased in all age categories and in 
both sexes; it increased exponentially with age and was higher in men than women at all ages 
(Figure 2). The most significant increase in prevalence from 2000 to 2016 was observed in 
patients aged ≥85 years: doubling in men from 11.6% (95%CI 10.4-11.6) to 22.1% (21.6-
22.6), p<0.001; and increasing by almost three quarters in women from 9.6% (9.2-9.9) to 
16.5% (16.2-16.9), p<0.001. The age distribution of patients included in the ≥85 years age 
category did not change over this time period: the median age and IQR remained constant 
between 2000 and 2016 at 88 (IQR 86-91) years; the increase in prevalence was therefore not 
driven by an increase in age. 
Treatment of AF 
1,031,122 records of patients with AF from 744 general practices were included in the 
treatment analysis across the 17 census dates, with a median of 64,080 (IQR 48,832-75,255) 
patients per year. Demographic characteristics are presented in Table 1. In 2000 the mean 
(standard deviation, SD) age of patients with AF was 74.5 (10.9) and 51.8% were male, and 
in 2016 the mean age was 75.5 (11.1) and 51.8% were male. A greater proportion of AF 
patients were in the lowest (least deprived) Townsend quintiles than the highest (most 
deprived) quintiles; the distribution across the Townsend quintiles changed little between 
2000 and 2016. 
Between 2000 and 2016, the proportion of patients with AF prescribed anticoagulants 
increased from 34.3% (95%CI 33.7-34.9) to 71.5% (71.1-71.8), p<0.001 for increase over 
time. The proportion prescribed antiplatelet drugs only decreased from 32.4% (31.8-33.0) to 
12.2% (12.0-12.5), p<0.001 for decrease over time. The proportion receiving no medication 
for stroke prevention decreased from 33.3% (32.7-33.9) to 16.3% (16.0-16.6), p<0.001 
(Figures 3–5). The case-mix of patients with AF also changed over the 16 year period: the 
proportion of patients with CHA2DS2-VASc score ≥2 increased from 86.9% (86.4-87.3) in 
2000 to 90.3% (90.1-90.6) in 2016 (p<0.001) (Supplementary Table 3). This is probably in 
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part due to the corresponding increase in the proportion of patients with AF aged ≥75 years 
(from 56.0% to 58.1%; p<0.001).  
Among high stroke risk patients with AF (CHA2DS2-VASc ≥2), the proportion prescribed 
anticoagulants increased steadily from 35.4% (95%CI 34.7-36.1) in 2000 to 75.5% (75.1-
75.8) in 2016, p<0.001. In moderate stroke risk patients with AF (CHA2DS2-VASc=1 and 
male), it increased from 32.8% (30.5-35.2) to 47.1% (45.4-48.7), p<0.001. In low stroke risk 
patients with AF (CHA2DS2-VASc=0 for males or 1 for females), the proportion prescribed 
anticoagulants decreased from 19.9% (17.8-22.2) to 9.7% (8.4-11.1), p<0.001 (Figure 3, 
Supplementary Table 3). 
In high risk patients, lone antiplatelet prescribing remained relatively constant at over 35% 
between 2000 and 2007, decreased modestly to 2011, and then steadily dropped to 12.3% 
(95%CI 12.1-12.6) in 2016, p<0.001. In moderate risk patients, lone antiplatelet prescribing 
increased from 20.7% (18.8-22.8) in 2000 to a high of 38.4% (37.1-39.8) in 2011 and then 
dropped to 14.9% (13.8-16.1) in 2016, p<0.001. In low risk patients it increased from 9.2% 
(7.8-10.9) in 2000 to 25.5% (23.9-27.3) in 2010, and then decreased to 4.9% (4.0-5.9) in 
2016, p<0.001 (Figure 4). In all patients with AF, lone antiplatelet prescribing has decreased 
substantially since 2011. 
The proportion of patients with AF receiving neither anticoagulant nor antiplatelet treatment 
decreased in high risk patients from 29.6% (95%CI 29.0-30.3) in 2000 to 12.2% (11.9-12.5) 
in 2016, p<0.001. In moderate risk patients it decreased from 46.5% (44.0-48.9) to 38.0% 
(36.5-39.6), p<0.001. In low risk patients, it increased from 70.9% (68.3-73.3) to 85.5% 
(83.8-87.0) in 2016, p<0.001 (Figure 5). 
Defining stroke risk by CHADS2 score made little difference to the proportion of patients 
with high risk who were prescribed anticoagulants, or to trends over time: the proportion 
treated increased from 37.0% (95%CI 36.2-37.9) in 2000 to 78.3% (77.9-78.7) in 2016 
(p<0.001). A greater proportion of patients were defined as having moderate risk 
(CHADS2=1), with the proportion treated following a similar trend to that in high risk 
patients, increasing from 32.2% (31.1-33.4) in 2000 to 63.4% (62.6-64.2) in 2016 (p<0.001). 
Similarly, a greater proportion of patients were designated as low risk (CHADS2=0), and of 
these more were treated, with the proportion remaining relatively constant over time: 25.4% 
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(23.7-27.1) in 2000 and 25.2% (23.8-26.7) in 2016 (Supplementary Figure 1, Supplementary 
Table 4). 
Defining treatment eligibility according to CHA2DS2-VASc score and presence or absence of 
contraindications to anticoagulants made no difference to the proportions of eligible patients 
with moderate or high stroke risk prescribed anticoagulants, or to trends over time. However, 
when ineligible patients include those with contraindications, the proportion of ineligible 
patients prescribed anticoagulants was greater, and increased from 28.1% (95%CI 26.3-29.9) 
in 2000 to 47.5% (46.1-48.9) in 2016, p<0.001 (Supplementary Figure 2, Supplementary 
Table 5); this is driven by treatment of patients with AF with contraindications.23 
NOACs first appear in the study population in 2009, at which time less than one patient in 
10,000 receiving anticoagulant treatment was prescribed NOACs; the proportion has 
increased substantially since, reaching 38.1% in 2016. There has been a corresponding drop 
in the proportion of anticoagulated patients with AF prescribed warfarin, from 99.3% in 2009 
to 64.0% in 2016. (The sum of percentages in 2016 is greater than 100% as some patients 
were prescribed both types of anticoagulant.) 
Variation in diagnosis and treatment of AF between general practices and 
performance over time 
The IQR for age-sex standardised AF prevalence at individual practice level was 1.6-2.5% in 
2000 and 2.9-3.6% in 2016, in patients aged 35 and over. 
In 2000, the proportion of eligible patients (CHA2DS2-VASc ≥1 and male or ≥2 and female) 
with AF prescribed anticoagulants in the highest-performing practice quintile was 48.0% 
(95%CI 46.2-49.7), compared to 23.5% (22.2-24.9) in the lowest-performing quintile. By 
2016, this had increased to 82.9% (82.2-83.7) and 62.0% (61.0-63.0) in the highest- and 
lowest-performing quintiles respectively. The proportion of eligible patients with AF 
prescribed anticoagulants increased at a similar rate in the top and bottom practice-level 
prescribing quintiles (defined according to the proportion of eligible patients with AF 
prescribed anticoagulants). The gap in anticoagulant prescribing to eligible patients with AF 
has therefore remained relatively constant, decreasing slightly from 24% in 2000 to 21% in 
2016 (Figure 6). 
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276 practices contributed data in every year from 2006 to 2016 (equivalent to 38% of the 734 
practices included in the analysis from 2006 to 2016, and 70% of the 398 practices 
contributing data in 2016). Over this period, 22.5% of practices remained in the same 
anticoagulant prescribing quintile; 59.1% remained in the same or adjacent quintile 
(Supplementary Figure 3). Linear-weighted κ=0.10 (95%CI 0.02-0.19), indicating poor 
agreement in practice prescribing performance over time. 
Discussion 
Age-sex standardised prevalence of diagnosed AF increased by 50% between 2000 and 2016 
to 3.3% in those aged ≥35 years. AF prevalence recorded in 2015/16 Quality and Outcomes 
Framework (QOF, a scheme to financially incentivise chronic disease management) data is 
around 3.1%* of adults aged ≥35 years.24,25 As this study use a wider range of clinical codes 
for AF, a slightly higher prevalence in the study data is to be expected.26 The increase in 
recorded prevalence may be partially due to improved identification and increased survival of 
patients with AF. There may also be an increased incidence of diagnosed AF over the study 
period, particularly patients aged 75 and over.27 
The proportion of eligible patients with AF (CHA2DS2-VASc ≥1 and male or ≥2 and female) 
treated with anticoagulants has doubled over 17 years with an increase in the rate of change 
after 2011. This corresponds to a change in European guidelines to recommend the treatment 
of moderate to high risk AF patients with anticoagulants rather than antiplatelets10 as well as 
a change in QOF to incentivise prescribing of anticoagulants.28,29 Changes in the guidelines 
and QOF may also explain the substantial drop in antiplatelet prescribing observed after 
2011. There is a further slight increase in prescribing rate between 2013 and 2015, most 
likely due to the recent introduction of CHA2DS2-VASc as the scoring system in QOF.8,22 It 
is possible that the continuing increase in prescribing rates may also be influenced by the 
introduction of a wider range of anticoagulant medication options (NOACs). 
                                                 
*
 Age-specific prevalence data was not available in QOF. In ONS data for England, 56% of the population are 
aged 35 years and above; almost all AF cases will be in this population. Therefore, approximate AF prevalence 
in those aged 35 and above = overall AF prevalence / 56% = 1.71/0.56 = 3.1%. 
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The proportions treated in the 2007 to 2010 THIN data are very similar to those reported in 
an analysis of QResearch primary care data, comprising data from practices using EMIS 
software, from 2007 to 2010.13 
In 2016, over three quarters of high-risk patients were prescribed anticoagulants, although 
less than half of patients with moderate stroke risk were treated. Anticoagulation rates in high 
risk patients are approaching the highest rates reported in European studies.18,19 The 
proportion of ineligible patients (CHA2DS2-VASc=0 in males or 1 in females) prescribed 
anticoagulants halved over the study period to around 10%; much higher proportions have 
been reported internationally, although these studies are now several years old and rates are 
likely to have changed.18,19,30,31 
There is substantial variation in prescribing performance between practices, suggesting that in 
any future interventions aimed at improving treatment rates, it may be beneficial to target 
more poorly performing practices. However, there is some evidence of inconsistency in 
individual practice prescribing performance over time: three fifths of practices maintained 
similar performance levels between 2006 and 2016, while two fifths showed a marked 
decline or improvement relative to other practices. 
Strengths and limitations 
This analysis was performed in a large general practice dataset which is generalisable to the 
UK population; it is routine clinical data and is therefore the information which GPs use for 
clinical decision-making. AF diagnosis was often corroborated in the patient records, 
although it was not possible to confirm all AF diagnoses; however, in a sample of 131 
patients with AF diagnosed in UK primary care in 2006, 84% were found to have either a 
primary or secondary care ECG confirmation of their diagnosis.32 Care was taken to exclude 
patients with ‘AF resolved’. Paroxysmal, persistent and permanent AF were not 
distinguished, which may have led to a slight overestimate of the point prevalence of AF. 
Some anticoagulated patients may be omitted if they are managed entirely in hospital, and 
treatment rates may therefore be underestimated. However, this is attenuated by the inclusion 
of clinical codes for anticoagulant/international normalised ratio (INR) monitoring, in 
addition to prescription information, in the definition of anticoagulant use; furthermore, most 
anticoagulants are prescribed in primary care, and any underestimation is therefore likely to 
be small. Similarly, some patients may obtain over-the-counter aspirin without this being 
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recorded in their medical records, although a clinical code for over-the-counter aspirin use 
exists and was included in the analysis. 
The study is a cross-sectional analysis investigating treatment rates at specific time points, 
and does not, therefore, include information on treatment adherence or persistence. However, 
of the patients who had a prescription for anticoagulants within 90 days prior to the census 
date, 90.0% (increasing from 85.3% in 2000 to 92.5% in 2016) also had a prescription 91 to 
180 days prior to the census date (two or more consecutive prescriptions). 
Most variables were defined by the presence of relevant clinical codes in the primary care 
record. Diagnoses which are part of the QOF assessment are likely to be well recorded for 
most/all of the study period; clinically significant conditions, such as major bleed, which 
have important implications for prescribing of drugs other than anticoagulants, are also likely 
to be well recorded; however, recording of other medical conditions may be incomplete. 
Contraindications were defined in accordance with MHRA and NICE guidance;33,34 however, 
in some conditions there is evidence to suggest that the reduced stroke risk associated with 
anticoagulation may offset the risk of adverse events such as bleeding.35,36 
Conclusions 
Prevalence of diagnosed AF in the UK is increasing, in all age groups and in both sexes. The 
use of anticoagulants in patients with AF has improved greatly over the past 17 years, with a 
doubling in the proportion of eligible patients treated alongside a halving of treatment of 
ineligible patients. There remains scope for improvement in patients at moderate risk, 
particularly in the general practices with the lowest prescribing rates. 
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Table 1. Demographic characteristics of patients with AF, 2000-2016 
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
Population, n 21,730 30,030 39,378 45,982 51,682 59,264 62,962 66,151 71,605 73,865 75,490 77,976 80,674 78,072 75,020 64,080 57,161 
Age, mean (SD) 74.5 
(10.9) 
74.8 
(11.0) 
74.8 
(11.0) 
74.8 
(11.0) 
75.0 
(11.1) 
75.1 
(11.1) 
75.3 
(11.1) 
75.6 
(11.0) 
75.6 
(11.0) 
75.7 
(11.0) 
75.8 
(11.0) 
75.9 
(11.0) 
75.8 
(11.00 
75.7 
(11.1) 
75.7 
(11.1) 
75.6 
(11.1) 
75.5 
(11.1) 
Sex, % male 51.8 52.1 52.4 52.6 52.7 53.1 53.4 53.6 54.0 54.5 55.0 55.2 55.7 56.2 56.5 57.1 57.5 
Ethnicity† % 
                 
White 98.1 98.2 98.3 98.1 98.2 98.2 98.1 98.0 98.0 98.0 97.9 97.7 97.6 97.4 97.7 98.0 97.8 
Asian 1.2 1.1 1.0 1.0 1.0 0.9 1.0 1.1 1.0 1.1 1.2 1.3 1.3 1.4 1.3 1.1 1.2 
Black 0.3 0.4 0.4 0.4 0.3 0.3 0.4 0.4 0.4 0.4 0.5 0.5 0.5 0.5 0.5 0.4 0.4 
Mixed 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.2 0.2 0.2 
Other 0.3 0.3 0.2 0.5 0.4 0.4 0.5 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.4 0.4 0.5 
Townsend Score %                                   
1 (least deprived) 22.5 22.7 22.7 23.0 23.2 23.6 24.1 24.2 24.4 25.0 25.0 25.0 24.5 24.3 23.9 22.1 21.5 
2 20.6 21.1 21.4 21.9 22.0 21.8 22.0 21.9 22.4 22.6 22.7 22.5 22.2 22.3 22.4 22.1 21.4 
3 19.9 20.2 20.2 20.1 20.1 20.0 20.0 19.9 20.2 20.0 20.1 20.1 20.1 20.0 20.1 20.0 19.8 
4 17.6 17.4 17.5 17.4 17.2 16.8 16.6 16.5 16.5 16.1 16.0 16.0 16.2 16.0 16.0 16.4 16.3 
5 (most deprived) 12.2 11.7 11.5 11.5 11.3 11.0 10.8 10.7 10.7 10.5 10.5 10.3 10.6 10.4 10.2 10.7 10.9 
Missing 7.2 6.9 6.7 6.0 6.3 6.9 6.5 6.8 5.9 5.7 5.8 6.1 6.5 7.0 7.5 8.6 10.0 
CHA2DS2-VASc risk score 
%                  
Low (0 males,  1 females) 5.9 5.5 5.3 5.0 4.7 4.6 4.2 3.6 3.5 3.3 3.3 3.2 3.3 3.3 3.4 3.3 3.4 
Moderate (1 males) 7.2 7.0 7.0 6.9 6.8 6.8 6.7 6.6 6.5 6.4 6.3 6.3 6.1 6.1 6.1 6.3 6.3 
High (≥ 2) 86.9 87.5 87.7 88.0 88.5 88.6 89.1 89.8 90.1 90.3 90.4 90.5 90.6 90.6 90.5 90.4 90.3 
†Where recorded; note that ethnicity was missing in 61.3% of the patient records (decreasing from 82.8% in 2000 to 58.9% in 2016).
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Figures 
 
Figure 1. Prevalence of diagnosed AF in men and women aged 35 and over, 2000-2016 
Figure 2. Age and sex stratified prevalence of diagnosed AF, 2000-2016 
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Figure 3. Proportion of patients with AF prescribed anticoagulants stratified by CHA2DS2-
VASc score, 2000-2016 
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Figure 4. Proportion of patients with AF prescribed antiplatelets stratified by CHA2DS2-
VASc score, 2000-2016 
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Figure 5. Proportion of patients with AF prescribed neither anticoagulants nor antiplatelets 
stratified by CHA2DS2-VASc score, 2000-2016 
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Figure 6. Proportion of patients with AF prescribed anticoagulants by eligibility (CHA2DS2-
VASc ≥ 1 and male or ≥ 2 and female) and practice prescribing quintile over time, 2000-2016 
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